All tenders
W911SR23F0057

DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.

Department of the Army · United States

This tender closed on Wednesday, January 5, 2028. Browse open opportunities
View Source

Time Left to Bid

Closed

ClosedDefence & SecurityFederal

Basic information

Reference number
W911SR23F0057
Government level
Federal
Solicitation type
Defence & Security
Title
DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.
Source ID
usa-W911SR23F0057

Details

Location
United States

Description

DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. Awarded to: RESILIENCE GOVERNMENT SERVICES, INC. Agency: Department of Defense Sub-agency: Department of the Army Award type: DELIVERY ORDER

Dates

Publication
2023/03/07 12:00:00 AM UTC
Closing date
2028/01/05 12:00:00 AM UTC

Estimated value

$4.3M USD

Classification

Normalized category

Defence & Security

Source: USASpending (Federal)

Last updated 2026-05-25, 2:08:04 p.m.

Data refreshed every 2 hours